Enavatuzumab
Enavatuzumab Basic information
- Product Name:
- Enavatuzumab
- Synonyms:
-
- Enavatuzumab
- Research Grade Enavatuzumab(DHJ62201)
- Research Grade Enavatuzumab
- Enavatuzumab (anti-TWEAKR)
- CAS:
- 1062149-33-0
- MW:
- 0
- Mol File:
- Mol File
Enavatuzumab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Enavatuzumab Usage And Synthesis
Uses
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo [1] [2].
in vivo
Enavatuzumab (10mg/kg; IP; three times per week; 7 doses) shows diverse antitumor activities on different xenograft tumors[1].
| Animal Model: | 6-week old SCID mice with SN12C or HCT116 or DLD-1 or A375 tumors[1] |
| Dosage: | 10mg/kg |
| Administration: | IP; three times per week; 6 doses (DLD-1 model), 7 doses (SN12C model), 9 doses (A375 or HCT116 model) |
| Result: | Some TweakR-expressing cells, such as SN12C and A375, were sensitive in vivo and in vitro. Some TweakR-expressing cell lines, such as HCT116 and DLD-1, were not sensitive to enavatuzumab treatment in vivo, though both cell lines were effectively killed via ADCC in vitro. Up-regulated the activation markers on splenocytes in SN12C tumor-bearing mice. |
References
[1] Shiming Ye, et al. Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells. J Immunol Res. 2017;2017:5737159. DOI:10.1155/2017/5737159
[2] Ludmilla de Plater, et al. Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts. PLoS One. 2014 Nov 6;9(11):e104227. DOI:10.1371/journal.pone.0104227
EnavatuzumabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 4008200310
- marketing@tsbiochem.com